Plain-English translation of NCT07294638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging probe called VE/CX-FTn-ICG that glows under special light to help surgeons see which lymph nodes contain cancer during gastric cancer surgery. The probe is designed to target cancer cells specifically, making it easier for doctors to identify which lymph nodes need to be removed and which ones are safe to leave behind.
Many early gastric cancer patients undergo surgery to remove lymph nodes as a precaution, even though most of these lymph nodes are actually healthy. This trial exists to develop a better way for surgeons to tell the difference between cancerous and non-cancerous lymph nodes during surgery, so patients can avoid unnecessary removal of healthy tissue and recover better.
You likely qualify if…
You likely don't qualify if…
If you enroll in this trial, the research team will inject the new fluorescent probe into your freshly removed gastric cancer tissue in the laboratory and use special imaging equipment to see which lymph nodes light up. This testing happens on the tissue after it has been surgically removed — you will not have the probe injected into your body. The results will help your surgical team better understand which lymph nodes contain cancer.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China